Astion Pharma (Three Products Worldwide Rights) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
Astion Pharma (Three Products Worldwide Rights) General Information
Description
Portfolio of manufacturing rights for three dermatological drugs. The portfolio encompasses worldwide rights for Dermadexin, a topical treatment for seborrheic dermatitis; Pruridexin, a topical cream to treat chronic puritis; and ASF-1096, a treatment for discoid lupus erythematosus.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Primary Office
- Denmark
Astion Pharma (Three Products Worldwide Rights) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.
Request a free trialAstion Pharma (Three Products Worldwide Rights) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.
Request a free trial